Approval Audited financial Results
ACI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.6 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Archean Chemical Industries reported a weak FY25 with standalone revenue from operations falling to Rs. 1,013.79 crore from Rs. 1,329.58 crore last year, a drop of about 24%. Standalone profit after tax (PAT) plunged to Rs. 184.92 crore from Rs. 322.35 crore, down roughly 43%, mainly due to a one-time exceptional charge of Rs. 40.18 crore and lower operating income. EBITDA margins also shrank year-on-year. Q4 FY25 was relatively stable with revenue of Rs. 321.77 crore and PAT of Rs. 58.31 crore. The board recommended a final dividend of Rs. 1.50 per share (75%) and reappointed the same statutory auditor, PKF Sridhar & Santhanam LLP, which issued an unmodified (clean) opinion on the results. HVS & Associates was appointed as the new Secretarial Auditor for five years.
Sharply lower revenue and profit, along with margin compression, signal a tough year for shareholders and may weigh on near-term stock sentiment, though the clean audit, dividend payout, and continued strategic investments in semiconductor and energy storage businesses offer some positives for long-term investors.